A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Frequency of local reactogenicity signs and symptoms after receipt of any study vaccine,Frequency of systemic reactogenicity signs and symptoms after receipt of any study vaccine,Number of serious adverse events (SAEs) leading to early participant withdrawal or permanent discontinuation,Number of medically attended adverse events (MAAEs) leading to early participant withdrawal or permanent discontinuation,Number of adverse events of special interest (AESIs) leading to early participant withdrawal or permanent discontinuation,Number of adverse events (AEs) leading to early participant withdrawal or permanent discontinuation,Part C only: Frequency of the CD4BS and CH505M5, G458Y, GNT1-specific, N280D KO IgG+ memory B cells, as assessed by flow cytometry,Part C only: Response rate of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by TZM-bl assay,Part C only: Magnitude of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by TZM-bl assay

This is a multicenter, open-label, phase 1 clinical trial to test two human immunodeficiency
 virus (HIV) vaccines with two adjuvants. An adjuvant is an ingredient used with some vaccines
 that may help people make an immune response. HIV is the virus that causes acquired
 immunodeficiency syndrome (AIDS).
 
 About 42 people will take part in the HVTN 309 clinical trial. This clinical trial will take
 place at multiple sites in the US and South Africa and the clinical trial is divided into 3
 parts: Part A, Part B and Part C. About 3 people will participate in Part A of this study.
 After results from Part A are reviewed, it will be determined whether or not Part B and Part
 C of the clinical trial will proceed.